AzTrials
AzTrials

Airway Complication of AnesthesiaADEPT1NCT03664700

Observational Study of the LMA Protector

An observational study of Airway Complication of Anesthesia, run by Oxford University Hospitals NHS Trust at 5 sites in United Kingdom.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The investigators want to investigate the user friendliness, and performance of the LMA Protector. The principal research question is to assess the overall performance of the LMA Protector. The investigators are merely making observations related to use of the device during clinical practice. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Airway Complication of Anesthesia
What is being tested?
LMA Protector
Type of treatment
Medical device
How many people
112 participants
Where
5 sitesUnited Kingdom
Study dates
5 Nov 2019to 1 Aug 2021
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients undergoing operation under general anaesthesia with a supraglottic airway device

Who may be able to join

  • Adult participants who are having a general anaesthetic.
  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • ASA 1 - 3 category patients
  • Elective operations
  • Urgent operations
  • Patients suitable for an SAD based on patient and operation factors.

Who cannot join

  • The participant may not enter the study if ANY of the following apply:
  • Refusal of consent
  • Age less than 18 years
  • Require intubation for the operation
  • Risk of regurgitation
  • ASA 4 and above
  • Mouth opening less than 2.5cm Require awake intubation

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

United Kingdom5 sites
  • Royal United Hospital

    Bath

  • Aneurin Bevan University Health Board

    Cardiff

  • Nothampton General Hospital

    Northampton

  • Oxford University Hospitals

    Oxford

  • Royal Berkshire Hospital

    Reading

Other trials in United Kingdom

About this study

Official title: ADEPT 1 - Observational Study of the LMA Protector

The investigators want to investigate the user friendliness, and performance of the LMA Protector. The principal research question is to assess the overall performance of the LMA Protector. The investigators are merely making observations related to use of the device during clinical practice.

Read the detailed description

There is a lack of research data on regarding the use of the LMA Protector. There is no regulatory requirement to collect or publish patient data on any device, either before CE marking or after. These devices are freely purchased and used.

There is, however, a professional duty to know that a device conforms to established norms for use. These norms are not official standards but rather, reference data against which a device can be clinically judged. Therefore, a device that is easy to insert but has a low 'leak pressure' (see above) is different from one that is more difficult to insert but as a high leak pressure. It is not that one is 'better' than the other, but rather that the data help create a 'usability profile' of the device which can be useful when making a clinical selection for the device.

Preoperative assessment:

During the preoperative visit, patient information leaflet will be given to the patients meeting the eligibility criteria.

Wherever possible, suitable patients will be identified in the preoperative assessment clinic and the information leaflet given. The patients will be given adequate time to read this information and any queries will be answered before being asked to sign a consent form. A detailed airway assessment will be performed by one of the investigators and documented on the study proforma.

Induction of anaesthesia:

On arrival in the anaesthetic room patients will be monitored with pulse oximetry, electrocardiography and invasive or non-invasive blood pressure measurements. After intravenous access is secured and the pre-surgical checklist completed, all patients will be pre-oxygenated using a facemask to achieve end tidal oxygen concentration of at least 80%. A 'sniffing' position of the head and neck and a 20 degree head-up bed tilt will be used for pre-oxygenation. General anaesthesia will be induced intravenously. After induction of anaesthesia, facemask ventilation will be commenced and anaesthesia maintained with an inhalational anaesthetic agent in oxygen or with total intravenous anaesthesia. The volatile agent's (anesthetic gases) concentration of 1 MAC adjusted for the patient's age will be achieved and maintained. This is normal process of anaesthesia applicable for all patients irrespective of participation in the study.

Supraglottic airway device (SAD) insertion:

Once deep plane of anaesthesia is confirmed, with the absence of movement to jaw thrust stimulation the SAD (LMA protector) will be inserted. The size of the device will be based on the manufacturer's recommendations for the body weight. The breathing system will be connected to the device. Ventilation of the lungs will be then confirmed by observing adequate bilateral chest inflation and square end-tidal capnogram wave with positive pressure ventilation. Adequate ventilation will be recorded if three tests are passed: 1) adequate chest movement, 2) an expired tidal volume of at least 7 ml/kg and 3) stable oxygenation. Time would continue until LMA® ProtectorTM inserted successfully. If it is not possible to insert the device or ventilate through it, two more attempts at placement of the device will be allowed. If placement has failed after two further attempts, the study will be abandoned and the other device will be used. If this fails on first attempt a different LMA or tracheal tube will be used as appropriate.

Maintenance of anaesthesia and recovery

The main interventions refer to the insertion of the airway device into the patient to obtain a airway and allow the conduct of the anaesthetic and therefore the surgery. However, if there are problems with the device and the airway obtained is suboptimal then the below interventions are allowed (which will be noted in the data collection form):

  1. Neck extension - move patient's neck upward
  2. Neck flexion - move patient's neck downward
  3. Chin lift - manoeuvre to open the airway
  4. Jaw thrust - manoeuvre to open the airway
  5. Reposition of the device At the end of operation, anaesthetic agents will be discontinued while the device is left in place. The device will be removed after the patient has regained consciousness, and has responded to verbal command to open the mouth. Any complications that occur during the use of the device will be recorded.

Postoperative assessment Postoperatively in recovery or on the ward, the investigators will visit each patient and determine whether the following airway complications are present after surgery: sore throat (constant pain, independent of swallowing), dysphagia (difficulty in, or pain provoked by, swallowing), sore jaw, dysphonia (difficulty in, or pain on, speaking), numbness of the tongue or the oropharynx, ear pain, neck or mouth ache, hearing changes. Each complication will be graded as none, mild, moderate or severe. The same questions will be asked 24-48 hours later.

First visit During the first visit by the anaesthetist to the participant, at the anaesthetist's earliest opportunity, either in the recovery area or on the ward, the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe.

  1. Vomiting
  2. Lip or tongue swelling
  3. Hearing changes
  4. Ear pain
  5. Sore throat
  6. Pain on swallowing
  7. Jaw pain
  8. Neck or mouth ache
  9. Pain on speaking
  10. Numbness of the tongue

Second visit (or telephone consultation) During the second visit 24-48 hours post-operatively on the ward or via telephone the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe.

  1. Vomiting
  2. Lip or tongue swelling
  3. Hearing changes
  4. Ear pain
  5. Sore throat
  6. Pain on swallowing
  7. Jaw pain
  8. Neck or mouth ache
  9. Pain on speaking
  10. Numbness of the tongue
Being tested
LMA Protector
Keywords
Supraglottic airway device, LMA Protector

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LMA ProtectorDevice

    The LMA Protector will be inserted when a supraglottic device is needed

Study groups in NCT03664700
Study groupRoleWhat they receive
LMA ProtectorThe LMA Protector will be used
Receives: Device: LMA Protector

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. First go Insertion Success Rate

    Whether insertion during first go was successful or not

    Measured: Day 1

  2. First go Successful Ventilation Rate

    Whether ventilation during first go was successful or not

    Measured: Day 1

  3. Number of Participants With Complication Free Insertions

    Number of participants with complication free insertions divided by total number of participants

    Measured: Day 1

Secondary outcomes (9)
  1. Time to First Square Capnography Waveform

    Record time in seconds of time to first capnography trace

    Measured: Day 1

  2. Lowest Oxygen Saturation Level

    Record of lowest oxygen saturation reading across all participants

    Measured: Day 1

  3. Interventions Needed to Ensure Airway Patency

    Collect number of predefined interventions needed to keep airway patent

    Measured: Day 1

  4. Number of Participants With Visible Chest Movement

    The success of ventilation will depend on whether there was visible chest movement

    Measured: Day 1

  5. Number of Participants With Adequate Tidal Volume at Attempt of Ventilation

    The success of ventilation will depend on whether there was tidal volume > 7ml/kg

    Measured: Day 1

  6. Number of Participants With Stable Oxygen Saturations

    The success of ventilation will depend on whether there was stable SpO2

    Measured: Day 1

  7. Number of Participants With Square Capnography Trace

    The success of ventilation will depend on whether there was square capnography trace

    Measured: Day 1

  8. Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal

    Collect number of pre-defined complications of device usage

    Measured: Day 1

  9. Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal

    Collect number of pre-defined complications of device usage. Secondary complication where asked about on Day 2 to ensure patients had recovered from the effects of the anaesthetic and are able to report any complications.

    Measured: Day 2

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2018
  2. Study start5 Nov 2019
  3. Primary completion1 Aug 2021
  4. Study completion1 Aug 2021

Why it stopped: Due to problems caused by the COVID-19 pandemic

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
112 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03664700
Sponsor's protocol ID
1338
Acronym
ADEPT1
Status last verified
Jan 2025
First submitted
26 Jul 2018
Last updated
14 Jan 2025
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data will be collected prospectively on data collection sheets completed by the anaesthetist / investigator during anaesthesia. Each site will manage their own data set and the data will be pooled at the end of the recruitment phase across all sites. Data will be sent from sites to the lead study team only at the end of the data collection. Consent form and initial data collection forms will be filed in the master folder and kept locked in the dedicated research locker in the department. The PI at each site will have access to this log. Each site will assign a study ID for each participant and a record of these IDs will be kept in the site file. Only anonymised data will be sent from each trust to the main study team. No personal data will be sent to the coordinating centre.

Questions about this trial

What is this clinical trial studying?

An observational study of Airway Complication of Anesthesia, run by Oxford University Hospitals NHS Trust at 5 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 14 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

First go Insertion Success Rate (time frame: Day 1). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in